Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Haemonetics (HAE) Operating Expenses (2016 - 2025)

Haemonetics has reported Operating Expenses over the past 17 years, most recently at $135.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses changed 0.35% year-over-year to $135.0 million; the TTM value through Dec 2025 reached $531.3 million, down 3.64%, while the annual FY2025 figure was $527.1 million, 0.09% changed from the prior year.
  • Operating Expenses for Q4 2025 was $135.0 million at Haemonetics, down from $136.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $146.0 million in Q1 2024 and troughed at $98.0 million in Q4 2021.
  • A 5-year average of $122.5 million and a median of $121.4 million in 2023 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 108.75% in 2021 and later decreased 16.61% in 2025.
  • Year by year, Operating Expenses stood at $98.0 million in 2021, then increased by 17.75% to $115.4 million in 2022, then increased by 14.26% to $131.9 million in 2023, then grew by 1.99% to $134.5 million in 2024, then rose by 0.35% to $135.0 million in 2025.
  • Business Quant data shows Operating Expenses for HAE at $135.0 million in Q4 2025, $136.3 million in Q3 2025, and $138.4 million in Q2 2025.